Spring Bank’s early inarigivir data ‘promising,’ says JMP Securities

After Spring Bank Pharmaceuticals reported data on the third cohort in the Phase 2 ACHIEVE trial of inarigivir in HBV patients that met the primary endpoints, safety and antiviral activity, at both week 12 and week 24, JMP Securities analyst Liisa Bayko called the early data “promising.” She thinks inarigivir has the potential to be an “integral piece to many iterations of combinations,” which could “put the company in play” if the evidence builds. Bayko reiterated her Outperform rating and $20 price target on Spring Bank shares.

https://bit.ly/2O7S6Su